HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Elliott, K. J. Articles by Inturrisi, C. E. Search for Related Content PubMed PubMed Citation Articles by Elliott, K. J. Articles by Inturrisi, C. E.

Dextromethorphan shows efficacy in experimental pain (nociception) and opioid tolerance

From the Pain Service, Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY.
Supported in part by the VZV Foundation (K.J.E.) and NIDA grant DA01457 (C.E.I.).
Address correspondence and reprint requests to Dr Elliott, Memorial Sloan-Kettering Cancer Center, Department of Neurology, Pain Service, 1275 York Avenue, New York, NY 10021.

The oral antitussive dextromethorphan is a clinically available N-methyl-D-aspartate receptor antagonist. Dextromethorphan has analgesic efficacy in the experimental formalin test, blocks the nociceptive activation of the immediate-early gene, c-fos proto-oncogene, and prevents and reverses the development of opiate analgesic tolerance in experimental models. These data suggest that dextromethorphan should be evaluated in a controlled clinical trial for analgesic efficacy in zoster-associated neuralgia.

NEUROLOGY 1995;45(Suppl 8): S66-S68